par Pagani, Olivia;Gallerani, Elisa;Abulkhair, OMalkahi;Pistilli, Barbara;Warner, Ellen;Saloustros, Emmanouil;Perey, Lucien;Zaman, Khalil;Rabaglio, Manuela;Gelber, Shari;Gelber, Richard;Ruggeri, Monica;Goldhirsch, Aron;Korde, Larissa;Abdel Azim, Hatem Hamdy 
;Partridge, Ann A.H.;Manunta, Silvia;Saunders, Christobel;Peccatori, Fedro Alessandro;Cardoso, Fatima ;Kaufman, Bella;Paluch-Shimon, Shani;Gewefel, Hanan
Référence Breast, 24, 3, page (201-207)
Publication Publié, 2015-06
;Partridge, Ann A.H.;Manunta, Silvia;Saunders, Christobel;Peccatori, Fedro Alessandro;Cardoso, Fatima ;Kaufman, Bella;Paluch-Shimon, Shani;Gewefel, HananRéférence Breast, 24, 3, page (201-207)
Publication Publié, 2015-06
Article révisé par les pairs
| Résumé : | Young patients with breast cancer (BC) are often concerned about treatment-induced infertility and express maternity desire. Conception after BC does not seem to affect outcome, but information in estrogen-receptor positive (ER+) disease is not definitive. From September 2012-March 2013, 212 evaluable patients with ER+ early BC, <37years at diagnosis, from 5 regions (Europe/US/Canada/Middle-East/Australia) answered a survey about fertility concerns, maternity desire and interest in a study of endocrine therapy (ET) interruption to allow pregnancy. Overall, 37% of respondents were interested in the study; younger patients (≤30 years) reported higher interest (57%). Motivation in younger patients treated >30 months was higher (83%) than in older women (14%), interest was independent of age in patients treated for ≤30 months. A prospective study in this patient population seems relevant and feasible. The International-Breast-Cancer-Study-Group (IBCSG), within the Breast-International-Group (BIG) - North-American-Breast-Cancer-Groups (NABCG) collaboration, is launching a study (POSITIVE) addressing ET interruption to allow pregnancy. |
